Business Wire

  1. Sanofi Chooses Snowflake To Accelerate Its AI-Powered Drug Development 6/2/2026

    SNOWFLAKE SUMMIT 26 – Snowflake, the AI Data Cloud company, today announced at Snowflake Summit 26 that Sanofi, one of the world's leading biopharmaceutical companies, has established a new blueprint for AI-powered biopharma with its launch of "Concierge for Field," a new AI agent built with Snowflake Cortex AI that prepares Sanofi's global sales representatives for every physician or provider visit.

  2. Biocytogen Launches AI-Powered RenSuper Platform And Industry-First Fully Automated Antibody Discovery Infrastructure 5/26/2026

    Biocytogen today announced the launch of RenSuper Workstation, a next-generation AI-powered antibody discovery platform providing off-the-shelf access to a large-scale, experimentally validated library of fully human therapeutic antibody sequences, together with the RenSuper High-Throughput Antibody Manufacturing Automation Center, a fully automated infrastructure designed to accelerate antibody validation and production.

  3. Curi Bio Launches The Curiverse At MPS 2026: The Industry's First Closed-Loop Ecosystem For Industrial-Scale, Human-Relevant Drug Discovery 5/26/2026

    Curi Bio, a global leader in functional human biology, today unveiled the Curiverse at the Microphysiological Systems World Summit (MPS) 2026, the industry’s first closed-loop ecosystem unifying assay-ready iPSC-derived cells, automated high-throughput systems, and cloud-based data analytics for industrial-scale 3D human drug discovery.

  4. Incyte And Genesis Expand Molecular AI Collaboration To Accelerate Drug Discovery 5/20/2026

    Incyte and Genesis Molecular AI today announced a significant expansion of their strategic collaboration building and deploying state-of-the-art AI to accelerate the discovery of novel molecules for collaboration targets selected by Incyte.

  5. QIAGEN To Advance AI-Driven Drug Discovery With Graph-Based AI And Curated Bioinformatics Knowledge With NVIDIA 5/19/2026

    QIAGEN announced at the 2026 BIO-IT World Conference & Expo in Boston that the QIAGEN Digital Insights bioinformatics business and its curated knowledge bases and bioinformatics expertise will be integrating NVIDIA accelerated computing and the NVIDIA BioNeMo platform to help researchers use AI more effectively in drug discovery.

  6. LenioBio And Twist Bioscience Enter Into A Collaboration To Further Enable AI Drug-Discovery 5/8/2026

    LenioBio GmbH, a TechBio company commercializing its ALiCE cell-free protein expression platform, today announced a collaborative agreement with Twist Bioscience Corporation.

  7. Altasciences And Certara Announce Strategic Partnership To Accelerate Early Drug Development 5/7/2026

    Altasciences, a fully integrated drug development solution company, and Certara, a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs.

  8. Waiv Enters Collaboration With Daiichi Sankyo To Deliver AI-Derived Biomarkers For ADC Program 5/6/2026

    Waiv, formerly Owkin Dx, a Paris-based company catalyzing AI precision testing, today announced it has entered a collaboration with Daiichi Sankyo to lead digital pathology biomarker discovery for an antibody-drug conjugate (ADC) program.

  9. Simulations Plus And NVIDIA Collaborate To Scale GPU-Accelerated, AI-Assisted Modeling Workflows 5/6/2026

    Simulations Plus, Inc. (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced the launch of a technical collaboration with NVIDIA focused on enabling GPU-accelerated simulation and AI-assisted workflows for computationally intensive modeling applications within the drug development lifecycle.

  10. Alloy Therapeutics And Institute For Protein Innovation Announce Strategic Collaboration To Advance Next-Generation Antibody Discovery 5/5/2026

    Alloy Therapeutics, a leading biotechnology ecosystem company, today announced a strategic collaboration with the Institute for Protein Innovation (IPI), a nonprofit leader in protein engineering and in vitro discovery.